Precision Medicine Initiative
Precision medicine encompasses all approaches that use patient- and disease-specific information to prevent, diagnose, and treat a disease. The increasingly widespread use of genome sequencing and genomic profiling has significantly improved the diagnoses and treatment of hematologic diseases by identifying unique variants that can be targeted with gene-based targeted therapeutic approaches including immunotherapies.
Applying the principles of precision medicine to hematologic diseases is a priority for ASH, and specific research recommendation are described in more detail in the ASH Agenda for Hematology Research.
Learn more about ASH's Precision Medicine Initiative activities below.
Enhancing Genomic Profiling of Blood Diseases
Molecular profiling of DNA and RNA has provided valuable new insights into the genetic basis of non-malignant and malignant hematologic disorders as well as an increased understanding of basic mechanisms that regulate hematopoiesis. The increasingly widespread use of genome sequencing and genomic profiling has significantly improved the diagnoses and treatment of hematologic diseases by identifying unique variants that can be targeted with gene-based targeted therapeutic approaches.
ASH has an enduring interest in enhancing genomic profiling of all hematologic diseases. This is evident in the Society’s programs and activities supporting this research priority and in the creation of a dedicated Subcommittee on Precision Medicine aimed at improving the use of molecular data in clinical care, research, and education.
The Society’s efforts can be categorized in the following key themes:

CAR-T Consortium
CAR-T Consortium
The Chimeric Antigen Receptor T-Cell (CAR-T) Consortium unites investigators from scientific and medical associations, government agencies, and registries, to address emerging toxicities associated with the application of CAR-T therapies.
Improving the Use of Immunotherapies for Hematologic Diseases
The field of immunology has generated novel immune-based strategies and improved the utility of existing treatment options for various hematologic diseases. As such, ASH has had an enduring interest in improving immunotherapies for all hematologic diseases. This is evident in the Society’s programs and activities supporting this research priority and in the creation of a dedicated Task Force on Immunotherapies to address specific scientific and clinical issues related to this area of precision medicine, specifically as it applies to hematology.
The Society's efforts can be categorized in the following key themes:
Special thanks for the development of this initiative are due to the following working groups
Acknowledgements
Acknowledgements
Questions?
For additional information about ASH’s immunotherapy activities, please contact ashprecisionmedicine@hematology.org.